Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance

By: via Benzinga
After hearing Neurotrope Inc (NASDAQ: NTRP) would announce results of its Phase 2 study of potential Alzheimer’s Disease (AD) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.